Gene test after stem cell transplant for AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses a very sensitive blood test (digital PCR) to look for tiny amounts of leftover leukemia after a stem cell transplant, focusing on certain gene changes that are not the common fusion genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML).
- You are getting a stem cell transplant at the study center.
- Your leukemia does not have the common fusion genes like AML1::ETO or BCR::ABL1.
- You had a special gene test (NGS) when first diagnosed, and we can see the results.
- Your initial leukemia did not have NPM1 mutations.
- At first diagnosis, you had clonal hematopoiesis (blood cell changes) or myelodysplasia-related gene changes (like DNMT3A, TET2, or others).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This trial uses a precise blood test called digital PCR to measure tiny amounts of leftover cancer cells in patients who have had a stem cell transplant. It helps doctors see how well the transplant is working and if more treatment is needed.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
This study uses advanced DNA testing to look for inherited gene changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It may help explain whether your illness could be part of a family-linked risk syndrome, which can guide treatment and family planning.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.